Published in Cancer Weekly, December 7th, 2004
Currently, VELCADE is being evaluated as a single agent in a company-sponsored, multicenter, phase II, clinical trial for the treatment of mantle cell lymphoma in addition to multiple investigator-initiated trials.
These trials are part of an ongoing research collaboration between Millennium and Johnson & Johnson Pharmaceutical Research & Development, LLC, to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.